Related Experiment Video
Updated: May 28, 2025
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Targeting PI4KB and Src/Abl host kinases as broad-spectrum antiviral strategy: Myth or real opportunity?
Maria Grazia Martina1, Daniele Rubini1, Marco Radi1
1Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Viale delle Scienze, 27/A, 43124, Parma, Italy.
Abstract:
Viruses pose a continuous threat to human health. Limited treatment options exist for current viruses, and the risk of infections with newly emerging or re-emerging viruses is increasing. In a pandemic scenario, having a broad-spectrum antiviral to limit viral spread while developing specific antivirals and vaccines is crucial. Targeting host kinases represents a valuable strategy due to the higher barrier to resistance and the broad-spectrum activity it offers. While cells have redundant kinases for the same biological function, viruses rely on specific kinases for their replication cycle, enabling targeted antiviral action with limited toxicity. This review focuses on two extensively studied kinase targets: the lipid kinase phosphatidylinositol 4-kinase IIIβ (PI4KB) and the tyrosine kinase proteins Src and Abl. Compounds active against these targets are reviewed in terms of the viruses they inhibit, their mechanisms of action and their stage of development. While PI4KB inhibitors have reached clinical trials, those targeting Src and Abl remain largely in the preclinical phase. Nevertheless, opportunities exist to improve potency and further understand the specific roles of these kinases in the life cycle of multiple viruses.
Insights
Broad-spectrum antivirals targeting host kinases, like phosphatidylinositol 4-kinase IIIβ (PI4KB) and Src/Abl tyrosine kinases, offer a crucial strategy against viral threats. PI4KB inhibitors are in clinical trials, while Src/Abl inhibitors are preclinical, highlighting development opportunities.
Area of Science:
- Virology
- Biochemistry
- Drug Discovery
Background:
- Viruses present an ongoing global health challenge with limited treatment options.
- Emerging and re-emerging viral threats necessitate broad-spectrum antiviral strategies.
- Host-targeting antivirals, particularly kinase inhibitors, offer a promising approach due to high resistance barriers and broad activity.
Purpose of the Study:
- To review antiviral compounds targeting host kinases, specifically phosphatidylinositol 4-kinase IIIβ (PI4KB) and Src/Abl tyrosine kinases.
- To analyze the viruses inhibited, mechanisms of action, and developmental stages of these kinase inhibitors.
- To identify opportunities for improving antiviral potency and understanding kinase roles in viral replication.
Main Methods:
- Literature review of scientific publications and clinical trial data.
- Analysis of compounds targeting PI4KB, Src, and Abl kinases for antiviral activity.
- Evaluation of the mechanisms of action and developmental progress of identified inhibitors.
Main Results:
- Compounds targeting PI4KB have advanced to clinical trials for antiviral applications.
- Inhibitors targeting Src and Abl tyrosine kinases are primarily in the preclinical development phase.
- The review details specific viruses affected and the modes of action for these kinase inhibitors.
Conclusions:
- Targeting host kinases like PI4KB and Src/Abl is a viable strategy for broad-spectrum antiviral development.
- Further research is needed to enhance the potency of Src/Abl inhibitors and elucidate their precise roles in various viral life cycles.
- Advancements in PI4KB inhibitor development show promise, while Src/Abl inhibitors represent future therapeutic potential.
